The latest price target for Abeona Therapeutics (NASDAQ:ABEO) was reported by HC Wainwright & Co. on August 14, 2024. The analyst firm set a price target for $15.00 expecting ABEO to rise to within 12 months (a possible 170.27% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Abeona Therapeutics (NASDAQ:ABEO) was provided by HC Wainwright & Co., and Abeona Therapeutics reiterated their buy rating.

There is no last upgrade for Abeona Therapeutics

The last downgrade for Abeona Therapeutics Inc happened on November 30, 2021 when SVB Leerink changed their price target from $5 to $1 for Abeona Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $15.00 to $15.00. The current price Abeona Therapeutics (ABEO) is trading at is $5.55, which is out of the analyst’s predicted range.